Use of Tinted Contact Lenses for Concussion-Related Light Sensitivity

May 5, 2026 updated by: Candice Turner, University of Alabama at Birmingham
The purpose of this study is to gather pilot data on the effectiveness of daily disposable tinted contact lenses in reducing photophobia (light sensitivity) following a concussion, with the goal of facilitating the return to work or school.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Candice I Turner, OD
  • Phone Number: (205)934-0997
  • Email: citurner@uab.edu

Study Contact Backup

  • Name: Katherine K Weise, OD
  • Phone Number: (205) 934-6758
  • Email: kweise@uab.edu

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Recruiting
        • UAB Eye Care
        • Contact:
        • Contact:
          • Katherine K Weise, OD
          • Phone Number: (205) 934-6758
          • Email: kweise@uab.edu
        • Principal Investigator:
          • Candice I Turner, OD
        • Sub-Investigator:
          • Katherine K Weise, OD
        • Sub-Investigator:
          • Heidi Hernandez, OD
        • Sub-Investigator:
          • Mallory Wright, OD
        • Sub-Investigator:
          • Thom Houston, MD
        • Sub-Investigator:
          • Mark Swanson, OD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • diagnosed mild traumatic brain injury (concussion)
  • age 18 or older
  • Within 24 months of initial injury
  • experiencing symptoms of photophobia (light sensitivity), increased photophobia since the injury, or no symptoms of photophobia

Exclusion Criteria:

  • moderate or severe concussion
  • active infection or inflammation that contradicts the use of soft contact lenses
  • subjects unable to safely perform insertion and removal of the contact lenses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Participants with concussion and light sensitivity fit with broad band (clear) contact lens
UPSIS-2 scale 15-60, eligible participants score greater than or equal to 26 are fit in broad band (clear) contact lenses.
Device: broad band (clear) contact lenses
Participants will receive these contacts based on the results of the Utah Photophobia Symptom Impact Scale (survey).
Other Names:
  • BioTrue One Day
  • Infuse daily disposable contact lenses
  • Clariti 1 Day clear contact lenses
Active Comparator: Participants with concussion and light sensitivity fit with narrow band (tinted) contact lens
UPSIS-2 scale 15-60, eligible participants score greater than or equal to 26 are fit in narrow wavelength (tinted) contact lenses.
Device: Narrow band (tinted) contact lenses
Participants will receive these contacts based on the results of the Utah Photophobia Symptom Impact Scale (survey).
Other Names:
  • Altius contact lenses

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants that improved symptoms of light sensitivity with narrow band (tinted) contact lenses
Time Frame: Baseline, 1 week
Improvement in the Utah Photophobia Symptom Impact Scale version 2 (UPSIS-2) on a scale of 15-60. Anything over 26 is considered significant.
Baseline, 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Alabama at Birmingham

Investigators

  • Principal Investigator: Candice I Turner, OD, University of Alabama at Birmingham School of Optometry

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

April 1, 2027

Study Registration Dates

First Submitted

October 29, 2025

First Submitted That Met QC Criteria

October 29, 2025

First Posted (Actual)

October 31, 2025

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 5, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-300015049
  • Faculty development grant (Other Grant/Funding Number: Faculty development grant)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Concussion, Mild

Clinical Trials on Narrow band (tinted) contact lenses

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe